Health
ACROFAN – ACROFAN USA
Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial e…
Study published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection
First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September
NEW BRUNSWICK, New Jersey, July 30, 2020 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the v…
-
Business20 hours agoIs Warren Buffett’s Berkshire Hathaway the smartest investment you can make today?
-
General20 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people
-
General24 hours agoMandatory sentencing reinstated for some DVO breaches in NT after bill passes parliament
-
General20 hours agoTaiwan’s President Lai Ching-te calls for peace and dialogue with China while also calling for defence boosts